International Total $2.31 B  $2.45 B   down 6 percent

Worldwide Total $3.62 B  $3.79 B   down 4.6 percent

Nonprescription drugs/nutritionals $1.03 B  $1.08 B   down 5 percent

Women’s health $402 M   $477 M    down 15 percent

MEDICAL DEVICES & DIAGNOSTICS 2Q 2012  2Q 2011  Change

U.S. Total $2.95 B  $2.87 B  up 2.9 percent

International Total $3.61 B  $3.7 B   down 2.4 percent

Worldwide Total $6.57 B  $6.57 B  down 0.1 percent

Cardiovascular Care $504 M   $587 M   down 14 percent

Orthopedic Products $1.63 B  $1.47 B  up 11 percent

PRESCRIPTION DRUGS 2Q 2012 2Q 2011 Change

U.S. Total $3.09 B $3.24 B down 4.5 percent

International Total $3.2 B  $2.99 B up 6.8 percent

Worldwide Total $6.29 B $6.23 B up 0.9 percent

Remicade (immune disorders) $1.52 B $1.37 B up 11 percent

Simponi (immune disorders) $125 M  $67 M   up 87 percent

Stelara (psoriasis) $248 M  $176 M  up 41 percent

Levaquin (antibiotic) a $16 M   $159 M  down 90 percent

Prezista (HIV) $373 M  $313 M  up 19 percent  

Intelence(HIV) $91 M   $79 M   up 15 percent

Aciphex (heartburn) $232 M  $247 M  down 6 percent

Concerta (attention deficit disorder) a $268 M  $349 M  down 23 percent

Risperdal Consta (schizophrenia) $355 M  $404 M  down 12 percent              

Invega (schizophrenia) $337 M  $205 M  up 64 percent

Doxil (breast, ovarian cancer) $13 M   $138 M  down 91 percent

Zytiga (prostate cancer) $232 M  $49 M   up 373 percent

Velcade (multiple myeloma) $318 M  $347 M  down 8 percent 

Procrit (anemia from cancer/dialysis) $401 M  $475 M  down 16 percent

TOTAL SALES 2Q 2012  2Q 2010  Change

U.S. $7.36 B  $7.45 B  down 1.2 percent

International $9.12 B  $9.15 B  down 0.4 percent

Worldwide Total $16.48 B $16.6 B  down 0.7 percent

____

Source: Johnson & Johnson

a. denotes drug has recent generic competion.